Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
AstraZeneca ( (GB:AZN) ) just unveiled an update.
AstraZeneca PLC announced the appointment of Rene Haas and Birgit Conix as Non-Executive Directors, effective from January and February 2025, respectively. Rene Haas, currently CEO of Arm, brings extensive experience in technology and AI, while Birgit Conix, CFO of Sonova, brings significant financial and pharmaceutical industry experience. These appointments are part of AstraZeneca’s strategic board refreshment plan as four current directors near their tenure limits, potentially strengthening the company’s governance and industry positioning.
More about AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
YTD Price Performance: 0.92%
Average Trading Volume: 2,680,018
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £162.3B
See more insights into AZN stock on TipRanks’ Stock Analysis page.
